Arcadia Biosciences (United States)

Overview

Compare with SPINDLETOP OIL & GAS CO, Viking Global Technologies, Inc. or MEXCO ENERGY CORP, or pick any stock.

• TickerRKDA on Nasdaq¹
• IndustryCrude Petroleum & Natural Gas¹
• HeadquartersDavis¹
• Websitewww.arcadiabio.com
• Legal formcompany¹
• Incorporated inDE⁵
• Business address5956 Sherry Lane, Suite 2000, Dallas, Tx⁵
• Filer categoryNon-accelerated filer, Smaller reporting company⁵

See how the biggest companies compare on our leaderboards

Arcadia Biosciences (Nasdaq: RKDA) is a publicly traded American agricultural biotechnology headquartered in Davis, California focused on the development of traits to enhance crop quality and productivity. The company is partly owned by Moral Compass Corporation.³

Corporate structure

Arcadia Biosciences (United States) sits at the top of its group. 2 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

What it owns

What Arcadia Biosciences (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our corporate headquarters are located in Dallas, Texas. We believe that our leased space is adequate to meet our current needs and that, if needed, suitable additional or alternative space will be available to accommodate our operations.

Item 2 of the 10-K filed Mar 26, 2026.¹⁴

Leadership

Who has led Arcadia Biosciences (United States), and when. Pick a name to see everywhere that person has worked.

• Chief executive officerStanley Jacot Jr. Feb 4, 2022 to May 30, 2023¹⁵
• Chief executive officerMatthew T. Plavan Sep 10, 2019 to Jan 25, 2021¹⁶
• Chief executive officerRajendra D. Ketkar May 24, 2016 to Jun 7, 2019¹⁷
• Chief executive officerEric J. Rey May 14, 2015 to Feb 3, 2016¹⁸
• PresidentEric J. Rey May 14, 2015 to Feb 3, 2016¹⁸
• Chief financial officerMark Kawakami Jul 18, 2024 to now¹⁹
• Chief financial officerPamela Haley Sep 10, 2019 to Aug 18, 2022²⁰
• Chief financial officerMatthew T. Plavan Sep 12, 2016 to Aug 28, 2019²¹
• Chief financial officerThomas P. O'Neil May 14, 2015 to May 14, 2015²²
• Chief operating officerRoger Salameh Aug 8, 2016 to Aug 22, 2016²³

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorThomas J. Schaefer named Jan 27, 2026 to Jun 26, 2026⁴⁸

Timeline

1. Sep 15, 20268-K Executive or director change; Shareholder vote⁴⁹
2. Sep 4, 20268-K Listing notice or transfer⁵⁰
3. Aug 13, 20268-K Results of operations⁵¹
4. Aug 10, 20268-K Listing notice or transfer⁵²
5. Jul 2, 20268-K Executive or director change; Director nominations; Other events⁵³
6. Jun 15, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure⁵⁴
7. May 14, 20268-K Results of operations⁵⁵
8. Apr 3, 20268-K Change of auditor⁵⁶
9. Mar 26, 20268-K Results of operations⁵⁷
10. Feb 6, 20268-K Executive or director change⁵⁸
11. Jan 14, 20268-K Entered a material agreement; Unregistered sale of shares; Change to shareholders' rights⁵⁹
12. Dec 29, 20258-K Ended a material agreement; Regulation FD disclosure⁶⁰
13. Feb 4, 2022New chief executive Stanley Jacot Jr. becomes CEO¹⁵
14. Sep 10, 2019New chief executive Matthew T. Plavan becomes CEO¹⁶
15. May 24, 2016New chief executive Rajendra D. Ketkar becomes CEO¹⁷
16. May 14, 2015New chief executive Eric J. Rey becomes CEO¹⁸
17. 2002Founded Founded¹

Calendar

Coming up

1. Nov 6, 2026Reports results for the quarter ending Sep/2026⁶¹

When it reported results

1. Aug 13, 2026Reported quarterly or annual results⁵¹
2. May 14, 2026Reported quarterly or annual results⁵⁵
3. Mar 26, 2026Reported quarterly or annual results⁵⁷
4. Nov 7, 2025Reported quarterly or annual results⁶²
5. Aug 14, 2025Reported quarterly or annual results⁶³
6. May 8, 2025Reported quarterly or annual results⁶⁴
7. Mar 20, 2025Reported quarterly or annual results⁶⁵
8. Nov 12, 2024Reported quarterly or annual results⁶⁶

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

204 filings to the SEC since October 2021: 9 annual reports, 15 quarterly reports, 59 major events, 47 insider forms, 10 large holders, 2 private raises, 62 other. The latest 20:

1. Sep 30, 2026SCHEDULE 13G EDGAR
2. Sep 30, 2026S-8 EDGAR
3. Sep 15, 20268-K EDGAR
4. Sep 14, 20264 EDGAR
5. Sep 14, 20264 EDGAR
6. Sep 14, 20264 EDGAR
7. Sep 14, 20264 EDGAR
8. Sep 4, 20268-K EDGAR
9. Aug 14, 2026SCHEDULE 13G/A EDGAR
10. Aug 13, 202610-Q EDGAR
11. Aug 13, 20268-K EDGAR
12. Aug 10, 2026ARS EDGAR
13. Aug 10, 2026DEF 14A EDGAR
14. Aug 10, 20268-K EDGAR
15. Jul 31, 2026PRE 14A EDGAR
16. Jul 9, 2026424B3 EDGAR
17. Jul 8, 2026EFFECT EDGAR
18. Jul 2, 20268-K EDGAR
19. Jun 26, 2026D EDGAR
20. Jun 26, 2026S-3 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

9 open-market trades by officers, directors and large owners since October 2021: 9 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• MJL Manager LLCSCHEDULE 13G, 1 filing Sep 30, 2026⁶⁷
• ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 4 filings Feb 14, 2023 to Aug 14, 2026⁶⁸
• SABBY MANAGEMENT, LLCSCHEDULE 13G/A, 2 filings Jan 3, 2024 to Jan 3, 2025⁶⁹
• Moral Compass CorpSC 13D/A, 1 filing Jan 20, 2023⁷⁰
• INTRACOASTAL CAPITAL, LLCSC 13G/A, 1 filing Feb 11, 2022⁷¹
• Hudson Bay Capital Management LPSC 13G/A, 1 filing Feb 4, 2022⁷²

Stakes it holds

Arcadia Biosciences (United States) has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

• Above Food Ingredients Inc.SCHEDULE 13G Aug 19, 2025⁷³

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Jun 12, 2026Raised $4 million in a private offering of equity Form D: $11.4 million offered in all Form D
2. Jan 12, 2026Raised $2.1 million in a private offering of equity Form D: $6 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Arcadia Biosciences (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARArcadia Biosciences, Inc.²
• CIK0001469443
• Employer ID (EIN)81-0571538¹⁴
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company¹⁴
• Incorporated inDelaware¹⁴
• Fiscal year endsDecember 31²
• Industry code (SIC)1311 Crude Petroleum & Natural Gas²
• SEC reviewing officeOffice of Energy & Transportation, Division of Corporation Finance²
• Business address5956 Sherry Lane, Suite 2000, Dallas, TX²
• Phone214-974-8921²
• Shares outstanding2,409,211 as of Aug 6, 2026⁷
• Public float$5.7M as of Jun 30, 2025¹⁴
• AuditorDeloitte & Touche LLP, Tempe, AZ PCAOB ID 34; no auditor attestation of internal control over financial reporting¹⁴
• On EDGAR sinceAug 4, 2009²
• Filings596 in all: 4 (159), 8-K (138), 3 (36), 10-Q (35), CORRESP (22), 424B3 (16), UPLOAD (16), DEF 14A (14)²
  All 44 form types

  EFFECT (14), SC 13G/A (14), 10-K (11), S-8 (11), SC 13G (11), DEFA14A (10), S-3 (8), D (7), 425 (6), S-1 (6), 10-K/A (5), 4/A (5), 424B5 (5), 8-K/A (5), PRE 14A (5), S-1/A (5), 3/A (3), SC 13D/A (3), SCHEDULE 13G (3), ARS (2), CERTNAS (2), DRSLTR (2), S-3/A (2), SCHEDULE 13G/A (2), SEC STAFF LETTER (2), 424B4 (1), 8-A12B (1), 8-A12B/A (1), 8-A12G (1), CT ORDER (1), DRS (1), DRS/A (1), RW (1), S-4 (1), S-4/A (1), SC 13D (1)

• Latest filingsAnnual report (10-K) Mar 26, 2026
  Quarterly report (10-Q) Aug 13, 2026
  Proxy statement (DEF 14A) Aug 10, 2026
  Latest 8-K (8-K) Sep 15, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).¹⁴

Risk factors and legal proceedings

The risks Arcadia Biosciences (United States) names in Item 1A of its 10-K filed Mar 26, 2026: 18 risks under these headings, as written.¹⁴

• Risks Related to Our Business
• There is substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain further financing.
• Statements in this Report on Form 10-K concerning our future plans and operations are dependent on our ability to secure adequate funding and the absence of unexpected delays or adverse developments. We may not be able to secure required funding.
• We have a history of significant losses, which we expect to continue, and we may never achieve or maintain profitability.
• We will require additional financing and may not be able to obtain such financing on favorable terms, if at all, which could adversely impact our operations and ability to continue our business. Such additional funding may not be available, which would have a material adverse effect on our business, financial condition and results of operations and would materially and adversely affect our ability to continue operations.
• Arcadia’s gross profit margins on its consumer products may be impacted by a variety of factors, including but not limited to variations, in freight costs, pricing, customer requirements, market acceptance rate and promotional support costs.
• Competition is intense and if Arcadia is unable to compete effectively, its financial results will suffer.
• Arcadia depends on its key personnel and, if it is not able to attract and retain qualified technical and business personnel, it may not be able to continue its business.
• Arcadia’s business is subject to the risks of security breaches, including cybersecurity incidents.
• Arcadia may be required to pay substantial damages as a result of product liability, health and safety, or other similar claims for which insurance coverage is not available.
• Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.
• Changes to U.S. trade policy, tariff and import/export regulations may adversely affect our operating results.

Legal proceedings

From time to time, we may be subject to legal proceedings, actions, claims, suits, or investigations arising from the ordinary course of our business, including actions with respect to intellectual property claims, breach of contract claims, claims relating to our products, labor and employment claims and other matters. Any litigation or other proceedings could divert management time and attention, could involve significant amounts of legal fees and other fees and expenses, or could result in an adverse outcome having a material adverse effect on our financial condition, cash flows or results of operations. Actions, claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty. Except as described below, we are not currently involved in any legal proceedings that we believe are, individually or in the aggregate, material to our business, results of operations or financial condition. However, regardless of the outcome, litigation can have an adverse impact on us because of associated cost and diversion of management time.

The opening of Item 3, Legal Proceedings.¹⁴

Links

• Websitewww.arcadiabio.com¹
• X (Twitter)x.com/arcadiaag¹
• WikipediaArcadia Biosciences
• WikidataQ30285756
• SEC EDGARCIK 1469443